METHYL 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBOXYLATE, 95%, 100mg

4,4,5,5-Tetramethyl-2-(m-tolyl)-1,3,2-dioxaborolane>98.0%(GC)(T)1g

2-Amino-3-(5-methoxy-1H-indol-3-yl)propanoic acid, 95.0%, 250mg

{[4-(benzyloxy)phenyl]methyl}(butyl)amine, 95.0%, 2g

4-Chloro-6-(methoxymethyl)-pyrimidine, 95.0%, 1g

Xanthine monosodium salt, monohydrate, 96.0%, 1g

p-Toluic acid, 98%, for synthesis, 1 kg, plastic packaging.

C-[1-(4-Fluoro-benzenesulfonyl)-piperidin-3-yl]-methylamine hydrochloride, 95.0%, 100mg

4-Bromo-3-fluoro-6-nitro-2-(tetrahydrofuran-2-yl)aniline, 98%, 250mg

N-(2-chloroethyl)-4-methylbenzenesulfonamide, 1g

1-(TETRAHYDRO-2H-PYRAN-2-YL)-1H-INDAZOLE-4-CARBOXYLIC ACID, 95.0%, 1g

4-Chloro-3-hydroxypyridine, 98.0%, 100mg

2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide, 95.0%, 250mg